Insider Trading Activity Kite Pharma Inc. (NASDAQ:KITE) – EVP Sold 1,788 shares of Stock

Insider Trading Activity For Kite Pharma Inc. (NASDAQ:KITE)

David D. Chang , EVP of Kite Pharma Inc. (NASDAQ:KITE) reportedly Sold 1,788 shares of the company’s stock at an average price of 50.86 for a total transaction amount of $90,937.68 SEC Form

Insider Trading History For Kite Pharma Inc. (NASDAQ:KITE)

On 3/30/2015 Ran Nussbaum, Director, sold 193,730 with an average share price of $60.45 per share and the total transaction amounting to $11,710,978.50.

On 4/27/2015 Cynthia M Butitta, CFO, sold 10,000 with an average share price of $59.76 per share and the total transaction amounting to $597,600.00.

On 6/1/2015 Ran Nussbaum, Director, sold 80,760 with an average share price of $55.34 per share and the total transaction amounting to $4,469,258.40.

On 6/1/2015 Marc Better, VP, sold 9,000 with an average share price of $54.60 per share and the total transaction amounting to $491,400.00.

On 6/2/2015 Ran Nussbaum, Director, sold 305,434 with an average share price of $55.35 per share and the total transaction amounting to $16,905,771.90.

On 6/15/2015 Rizwana F Sproule, VP, sold 9,567 with an average share price of $56.98 per share and the total transaction amounting to $545,127.66.

On 6/15/2015 Margo R Roberts, Insider, sold 8,625 with an average share price of $56.99 per share and the total transaction amounting to $491,538.75.

Analyst Ratings For Kite Pharma Inc. (NASDAQ:KITE)
These are 2 Hold Ratings, 14 Buy RatingsThe current consensus rating for Kite Pharma Inc. (NASDAQ:KITE) is Buy (Score: 2.88) with a consensus target price of $73.23 , a potential (58.89% upside)

Analyst Ratings History For Kite Pharma Inc. (NASDAQ:KITE)

• On 5/5/2015 Credit Suisse Group AG Reiterated Rating Outperform with a price target of $79.00
• On 8/14/2015 Guggenheim Reiterated Rating Buy
• On 12/15/2015 Standpoint Research Upgraded rating Hold to Buy
• On 2/25/2016 Citigroup Inc. Initiated Coverage of rating Buy with a price target of $67.00
• On 3/20/2016 SunTrust Banks Inc. Reiterated Rating Buy with a price target of $70.00
• On 5/18/2016 Royal Bank Of Canada Reiterated Rating Buy
• On 6/2/2016 Raymond James Financial Inc. Initiated Coverage of rating Outperform with a price target of $61.00

About Kite Pharma Inc. (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Recent Trading Activity for Kite Pharma Inc. (NASDAQ:KITE)
Shares of Kite Pharma Inc. closed the previous trading session at 46.09 0.00 0.00% with 860,328 shares trading hands.